Kedrion Biopharma
Tommaso Paoli has extensive experience in the biopharmaceutical industry, particularly in the field of quality management. Tommaso began their career at Kedrion Biopharma in 2006 as a QA Plasma Release Associate and steadily progressed through various roles, including QA Statistics Responsible, Global QA Projects Coordinator, Global QA Auditing & Projects Manager, Group Plasma Quality Manager, Director of Quality Operations Melville, and Global Plasma Quality Director. From 2018 to 2019, they also served as the Director of US Quality Operations. In 2019, they were appointed as the Global Plasma Quality & Regulatory Director. Following this, they briefly held the role of Site Leader (Executive) at the Melville Plant before being promoted to their current position as Senior Vice President Global Quality, where they lead and executes the Quality strategy and goals for the entire company, including the plasma business unit. In addition to their time at Kedrion Biopharma, Tommaso also worked as the Director of Quality at KEDPLASMA from 2017 to 2018. Prior to their career in the biopharmaceutical industry, Tommaso obtained a PhD in Evolutionary Biology from the University of Pisa between 2002 and 2005. Tommaso is currently set to join BPL Plasma as the Senior VP of Global Quality in November 2022.
Tommaso Paoli obtained a Mini MBA in Business Administration and Management, General from Rutgers University in the year 2020. Prior to that, they pursued a degree in Biological Sciences at Università di Pisa from 1994 to 2001. Tommaso completed their high school education at Cavanis High School from 1989 to 1994. Moreover, Tommaso Paoli holds a Doctor of Philosophy - PhD in Biology/Biological Sciences, General from Università di Pisa.
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.